Overview

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital